Bambusa Therapeutics Secures $15 Million Seed Funding for Bispecific Antibody Development
Key Insights
Bambusa Therapeutics (search) has successfully closed a Series Seed financing round, raising approximately $15 million to advance its bispecific antibody programs.
The funding will support the development of Bambusa's pipeline of bispecific antibodies (search), aimed at treating immunological and inflammatory disorders (search), towards Phase I clinical studies.
Bambusa Therapeutics (search) is focused on creating best-in-disease bispecific antibody therapeutics by leveraging validated targets and innovative antibody engineering.
Bambusa Therapeutics (search) Inc., a biotechnology company specializing in bispecific antibodies (search) for immunological and inflammatory (I&I) disorders, has announced the successful completion of its Series Seed financing, securing approximately $15 million. This funding will propel the company's innovative antibody engineering efforts towards Phase I clinical studies.
Funding and Investment
The financing round was co-led by BVF Partners L.P. (search) and Dawn Biopharma (search), a platform controlled by KKR, with participation from Salvia GmbH (search) and INCE Capital (search). The investment reflects confidence in Bambusa Therapeutics (search)' approach to developing bispecific antibody therapeutics.
Therapeutic Focus and Innovation
Bambusa Therapeutics (search) is dedicated to transforming the treatment of I&I diseases by leveraging validated targets to create bispecific antibody therapeutics. The company aims to achieve best-in-disease profiles across multiple indications through innovative antibody engineering.
Executive Perspectives
"We founded Bambusa Therapeutics (search) with a belief that the I&I field is long overdue for innovative approaches and transformative therapeutics," said Dr. Shanshan Xu, CEO and Co-Founder of Bambusa Therapeutics. "Since our inception, we have built a diverse portfolio of molecules and is uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions."
Helmut Jeggle, Managing Director of Salvia GmbH (search) and Co-Founder of Bambusa Therapeutics (search), added, "We are thrilled to have the support of such distinguished investors who share our vision. This funding will allow us to strengthen the team to advance our lead candidates through preclinical development and position us for success in clinical studies."